· rebuilt nightly from public records
Signal Sheet
Ensysce Biosciences is a listed health care company in La Jolla, California. It raised $77.2M in Aug 2026 and its filings name 10 officers. Everything below links to the record it came from.
Officer or director change
New leadershipEquity raise reported to the SEC, Aug 2026.
CapitalSigned a material agreement
Corporate eventPick the companies and territory you sell to and get dated, sourced reasons like these for each one, ranked by who is most likely to buy now. Your list stays yours.
Want this matched to what you sell? Get early access to Pursuit Plans →The most recent events first, refreshed every night. Each links to the record it came from.
| When | What happened | Kind | Source |
|---|---|---|---|
| Oct 29, 2026 | Officer or director change | New leadership | SEC filing |
| Aug 5, 2026 | Raised $77.2M in equity from 44 investors | Capital | SEC filing |
| Aug 5, 2026 | Signed a material agreement | Corporate event | SEC filing |
| Aug 5, 2026 | Completed an acquisition or sale | Corporate event | SEC filing |
| Aug 5, 2026 | Officer or director change | New leadership | SEC filing |
| Jul 15, 2026 | Officer or director change | New leadership | SEC filing |
| Apr 7, 2026 | Signed a material agreement | Corporate event | SEC filing |
| Apr 3, 2026 | Officer or director change | New leadership | SEC filing |
The roles that matter for a seller right now. Names on this page come from SEC filings or the company's own announcements. Contacts you find with a free trial are verified before you see them. How we source names
| Role | Contact | Source | Why they matter now |
|---|---|---|---|
| Executive Officer | D Lynn Kirkpatrick | SEC filing, Aug 2026 | Named officer in the filing; part of the buying group |
| Executive Officer | David Humphrey | SEC filing, Aug 2026 | Named officer in the filing; part of the buying group |
| Executive Officer | James Morrison | SEC filing, Aug 2026 | Named officer in the filing; part of the buying group |
| Chief Technology Officer | Bob Gower | SEC filing, Aug 2026 | Technology and tooling decisions |
| Chief Technology Officer | William Chang | SEC filing, Aug 2026 | Technology and tooling decisions |
| Chief Technology Officer | Steve Martin | SEC filing, Aug 2026 | Technology and tooling decisions |
| Chief Technology Officer | Adam Levin | SEC filing, Aug 2026 | Technology and tooling decisions |
| Chief Technology Officer | Andrew Benton | SEC filing, Apr 2025 | Technology and tooling decisions |
| Chief Technology Officer | Curtis Rosebraugh | SEC filing, Apr 2025 | Technology and tooling decisions |
| Chief Technology Officer | Lee Rauch | SEC filing, Apr 2025 | Technology and tooling decisions |
Lakewave does the research, the stitching and the first draft with AI, so you spend your time selling.
Lakewave tracks raises, new leaders, hiring and filings across your accounts and territory, and tells you the day something changes.
Find the decision makers, get mailbox-verified addresses and an AI draft written for that account, which you review. Send from your own inbox with open and reply tracking and a follow-up sequence.
Which accounts to pursue, why now, who to reach and what to say, matched to your product and the buyers you sell to.
Every address Lakewave gives you is checked against Ensysce Biosciences's mail server before you see it. Guessed addresses bounce, and bounces are what push a sender's domain toward the spam folder, so one bad list can cost a rep weeks of deliverability. Lakewave shows how each address was confirmed and leaves out the ones it cannot verify.
Use it two ways. Look up the verified address you need for a call you are already planning. Or let Lakewave do the whole job: find the accounts with a reason to buy now, the right people and their addresses, and draft a first email for each person, so you are not stitching together data sources and research by hand.
Try it on Ensysce Biosciences with a free trial →| Headquarters | La Jolla, California, per the filing address |
| Industry group | Other Health Care |
| Ownership | Listed company |
| Raise history | $1.1M (Mar 2025) · $2.2M (Apr 2025) · $77.2M (Aug 2026) |
| Lakewave Rising | 38 · 3 kinds of evidence · rank in California after sign-up |
Private-sector companies in the same industry group and state, ranked by Rising score.
Yes. Ensysce Biosciences reported a $77.2M equity raise to the SEC on Aug 5, 2026 with 44 investors.
The company's SEC filing, Aug 2026 names D Lynn Kirkpatrick (Executive Officer) among its officers.
La Jolla, California, per the address on its SEC filing.
Select the accounts and territory you sell to and get dated reasons for every company: new budget, new leaders, new hires, with who to reach and a first draft for each contact.
Start your free trialEvery account you select comes back scored by what changed this month, with the source for each fact.
Named officers from filings and announcements, each with an address verified against the mailbox. No bounces, no guessed patterns, no scraped profiles.
Lakewave writes a first email for each person, tailored to their role and company. You edit, approve and send it from your own mailbox.
A weekly note on what changed across your targets, so no account moves without you knowing.
Free trial · No credit card · Built from public records, refreshed nightly
Compiled from public records and refreshed nightly; last updated Nov 10, 2026. Facts are as the SEC, the company's careers page or the company's own announcements published them. Check the source before acting. See something wrong? Tell us and we will correct it.